DOCSLIB.ORG

Kin-2787, Is Active in Class Ii and Class Iii Braf Mutant Models

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THE NEXT-GENERATION PAN-RAF INHIBITOR, KIN-2787, IS ACTIVE IN CLASS II AND CLASS III BRAF MUTANT MODELS Aleksandra Franovic, Nichol Miller, Paul Severson, Toufike Kanouni, Noel Timple, Ping Jiang, Eric Murphy, Eric S. Martin Kinnate Biopharma Inc., San Diego, CA JUNE 2021 2 KIN-2787 is a potent and selective pan-RAF inhibitor NTRK 3 EPHB2 FG FR1 NTRK 2 FG FR4 NTRK 1 KDR FLT1 CSF 1 R EPHB1 RO R2 EPHA5 KI T M USK RO R1 RET EPHB3 DDR2 M ERTK EPHA3 AXL FLT4 DDR1 TYRO 3 PDG FRA EPHA4 FLT3 I NSRR PDG FRB IG F1 R EPHA6 ERBB 2 I NSR EG FR YES1 M ET EPHB4 M ST 1 R M AP 3 K 11 SRC RO S 1 M AP 3 K 9 ALK TEK EPHA7 LYN TI E1 LTK ERBB 4 RYK HCK FYN M AP 3 K 21 EPHA8 PTK7 M AP 3 K 10 TNK1 TYK2 TNK2 J AK1 LCK FG R J AK2 ERBB 3 J AK3 EPHA2 BLK RI PK 4 ANKK 1 M AP 3 K 12 ZAP 70 PTK2 B SYK M AP 3 K 13 AATK EPHA1 PTK2 LM TK2 ACVR 1 B RAF 1 I TK TG FBR1 M AP 3 K 20 FRK TEC BRAF EPHB6 KSR1 RI PK 2 KSR2 SRM S TXK PTK6 I RAK 1 LM TK3 ACVR 1 C BTK I RAK 3 LI M K1 ARAF LI M K2 BM PR 1 B BM X EPHA10 TESK1 BM PR 1 A I LK M ATK M AP 3 K 7 TESK2 ACVRL 1 RI PK 3 CSK TNNI 3 K ACVR 1 ABL 2 ACVR 2 A FES I RAK 2 ABL 1 ACVR 2 B RI PK 1 FER TG FBR2 J AK3 • Oncogenic BRAF alterations are observed in ~6% of human M AP 3 K 2 AM HR 2 J AK2 LRRK 1 M AP 3 K 3 LRRK 2 BM PR 2 TYK2 M AP 3 K 5 STYK1 I RAK 4 M AP 3 K 19 NPR1 J AK1 M AP 3 K 15 NPR2 M AP 4 K 5 STK25 MOS STK4 STK3 M AP 4 K 1 M AP 4 K 3 G UCY 2 C STK24 DSTYK W NK1 M AP 3 K 6 M AP 4 K 2 STK26 DYRK 2 W NK3 PBK DYRK 3 M AP 3 K 4 G UCY 2 D W NK2 NRBP 2 M AP 4 K 4 DYRK 1 A NRBP 1 DYRK 4 O XSR1 G UCY 2 F M I NK 1 DYRK 1 B M AP 3 K 1 STK39 TNI K W NK4 NRK M LKL STRADA M YO 3 A EI F 2 AK3 STRADB TEX14 SLK M YO 3 B EI F 2 AK2 HI PK 3 TEX14 STK10 HI PK 1 EI F 2 AK4 cancers and lead to aberrantly activated BRAF monomers TAO K 1 SCYL 3 M AP 3 K 8 TAO K 2 HI PK 2 SCYL 1 M AP 3 K 14 TAO K 3 SCYL 2 PRPF 4 B PAK1 CLK4 EI F 2 AK1 HI PK 4 PAK3 PAK4 STK35 PAK2 CLK1 ERN1 PAK7 CLK2 M AP 2 K 5 PDI K 1 L ERN2 TBCK PAK6 CLK3 M AP 2 K 7 M AP 2 K 1 RNASEL EI F 2 AK4 M AP 2 K 2 TTK STKLD1 SRPK3 UHM K 1 M AP 2 K 3 SRPK2 PKM YT 1 M AP 2 K 4 M AP 2 K 6 SRPK1 CSNK 2 A 1 W EE1 CSNK 1 D M AK PO M K CSNK 2 A 2 CDC7 W EE2 TTBK1 TP53RK I CK CSNK 1 E G SK3 B G SG 2 TTBK2 G SK3 A MOK CSNK 1 A 1 CDKL 3 CSNK 1 A 1 L PI NK 1 PEAK1 CDKL 2 PKDCC VRK3 (Class I), homodimers (Class II) & heterodimers (Class III) CSNK 1 G 2 CDKL 5 M APK 15 CDKL 1 STK31 PRAG 1 CSNK 1 G 1 CDKL 4 M APK 4 PXK SBK3 M APK 6 CSNK 1 G 3 NLK PI K3 R 4 BUB1 SBK2 M APK 7 SBK1 BUB1 B CHUK VRK1 M APK 3 I KBKB PLK4 CDK7 VRK2 I KBKE M APK 1 TBK1 M APK 12 STK16 CDK11B M APK 8 TLK2 M APK 13 M APK 9 G AK PLK3 M APK 10 CDK10 AAK1 TLK1 ULK3 M APK 11 CAM KK 1 CDK8 PLK1 PLK2 CDK19 M APK 14 CDK4 CDK20 ADRBK 1 BM P 2 K CAM KK 2 G RK1 CDK6 ULK1 ADRBK 2 STK36 G RK5 G RK7 CDK15 ULK2 ULK4 G RK6 G RK4 CDK14 CDK9 NEK6 RPS 6 KC1 NEK7 NEK10 CDK17 PASK NEK8 STK40 PDPK1 RPS 6 KA1 RPS 6 KA5 RPS 6 KL 1 NEK9 STK11 RPS 6 KA4 CDK18 CDK12 RPS 6 KA3 CDK5 CDK13 CDK16 RPS 6 KA6 NEK2 CHEK 1 RPS 6 KA2 RPS 6 KB1 AKT 2 AKT 1 NEK11 AURKA RPS 6 KB2 AKT 3 CDK1 NEK4 CDK3 SG K1 AURKB CDK2 PKN1 TRI B 3 PI M 1 SG K2 SG K3 PI M 2 AURKC LATS1 PRKG 2 NEK3 PKN2 PI M 3 LATS2 PRKG 1 TRI B 2 PKN3 STK38 NEK5 O BSCN PRKY STK38L TRI B 1 STK32A PRKX SPEG PRKCH NEK1 M AST 3 O BSCN M ASTL PRKCE PRKCZ STK33 STK32B PRKCI PRKCD SPEG STK32C PRKCQ PRKACG PRKCG PRKACA TTN M AST 2 PRKACB TRI O • Approved BRAF inhibitors benefit patients with Class I BRAF M YLK KALRN RO CK 1 PRKCA CHEK 2 TSSK4 HUNK RO CK 2 > 90% inhibition PRKCB M YLK2 SNRK DM PK M AST 4 M AST 1 TSSK6 CI T STK17B NI M 1 K PRKD 2 TSSK3 STK17A DCLK 3 DCLK 1 CDC42BPG M YLK4 TSSK1 B DCLK 2 PRKD 1 TSSK2 M YLK3 M ELK PRKD 3 CASK DAPK 3 CDC42BPB DAPK 2 CAM KV PHKG 1 DAPK 1 M APKAPK 5 CDC42BPA PSKH1 M KNK 1 PHKG 2 PRKAA 2 PSKH2 M KNK 2 M APKAPK 2 CAM K 2 G PRKAA 1 CAM K 2 A CAM K 2 B CAM K 2 D > 75% inhibition BRSK 2 M APKAPK 3 CAM K 4 mutation-driven cancers (i.e., BRAF V600) but are not BRSK 1 RPS 6 KA6 NUAK 2 RPS 6 KA1 NUAK 1 RPS 6 KA5 RPS 6 KA4 PNCK SI K3 RPS 6 KA3 RPS 6 KA2 CAM K 1 G SI K1 SI K2 CAM K 1 CAM K 1 D > 50% inhibition M ARK 4 M ARK 3 M ARK 1 effective in patients with Class II or III BRAF alterations M ARK 2 Biochemical Assay KIN-2787 IC50 (nM) • KIN-2787 is an orally-available, potent and selective small ARAF 2.41 molecule pan-RAF inhibitor that inhibits Class II & III dimers, BRAF 3.46 in addition to Class I BRAF mutants BRAFV600E 1.53 RAF1 0.573 Kinase selectivity for KIN-2787 at 1000 nM across 653 kinases was established in single dose, duplicate measurements in a radiometric kinase • The activity of KIN-2787 was assessed in vitro and in vivo in assay (Reaction Biology Corp.). Percent inhibition is relative to DMSO control. IC50 values for RAF family kinases and selected off-targets were determined various BRAF-driven cancer models using a 4-parameter fit model from a 10-point dose response curve performed with 3 replicates at each drug concentration. Aleksandra Franovic, Ph.D. Director, Translational Medicine | Kinnate Biopharma Inc. 3 Single agent activity of KIN-2787 in BRAF-mutant cell lines pERK EC50 (nM) Tumor Cell Line Lineage BRAF Status MAPK Pathway Alteration(s) Binimetinib KIN-2787 A-375 Melanoma BRAFV600E 8 67 Class I Colo800 Melanoma BRAFV600E 5 112 BxPC-3 Pancreatic BRAFindel(VTAPTP) 3 51 OV-90 Ovarian Class II BRAFindel(NVTAP) 4 26 NCI-H2405 NSCLC BRAFindel(LNVTAP) 6 10 WM3629 Melanoma BRAFD594G, NRASG12D 5 9 Class III CAL-12T NSCLC BRAFG466V 3 18 MIA PaCa-2 Pancreatic KRASG12C 3 685 NCI-H358 NSCLC Wild type KRASG12C 1 351 CHL-1 NSCLC Wild type 5 580 For the evaluation of cellular potency, cells were treated with the indicated compounds for 1 hour and ERK phosphorylation (pERK) was measured in cell lysates using a homogenous time-resolved fluorescence assay. The compounds were run in 10-point, 3-fold serial dilutions starting at 10,000 nM to establish EC50 values using a 4-parameter fit model. All samples were run in triplicate and represent an average of 2 or more independent experiments. Aleksandra Franovic, Ph.D. Director, Translational Medicine | Kinnate Biopharma Inc. 4 KIN-2787 is efficacious in Class II and Class III BRAF-mutant human xenograft models BxPC3 Class II BRAF-mutant Pancreatic Cancer WM3629 Class III BRAF-mutant Melanoma TGI 109% TGI 101% TGI 118% TGI 101% 30% 30% Aleksandra Franovic, Ph.D. Director, Translational Medicine | Kinnate Biopharma Inc. 5 KIN-2787 suppresses MAPK pathway expression in vivo WM3629 Class III BRAF-mutant Melanoma – 3-day PK/PD Analysis Time- and exposure-dependent PD Reduction in MAPK target gene Reduction in pMEK and MAPK biomarker (pERK) inhibition RNA expression target gene protein levels 10 mg/kg 20 mg/kg Vehicle BID QD pMEK GAPDH 1 h MEK GAPDH EphA2 GAPDH 7 h DUSP6 GAPDH Time (Hours) Time (Hours) 1Wagle (Huang) et al. 2018 NPJ Precis. Oncol. Aleksandra Franovic, Ph.D. Director, Translational Medicine | Kinnate Biopharma Inc. 6 Conclusions • KIN-2787 has pronounced in vitro and in vivo activity against human cancers driven by Class I, Class II and Class III BRAF mutations • Time- and exposure-dependent inhibition of MEK-ERK phosphorylation was achieved and accompanied by suppression of MAPK transcriptional targets at the RNA and protein level • Twice daily (BID) dosing was well-tolerated, led to prolonged target coverage / inhibition and a trend towards more frequent and deeper tumor responses in vivo • A phase 1 dose escalation and expansion clinical trial evaluating the pharmacokinetics, safety and efficacy of KIN-2787 monotherapy in patients with advanced or metastatic solid tumors with BRAF gene alterations is expected to initiate in 2021 Aleksandra Franovic, Ph.D.
Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB

    Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB

    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
  • Reframing Psychiatry for Precision Medicine

    Reframing Psychiatry for Precision Medicine

    Reframing Psychiatry for Precision Medicine Elizabeth B Torres 1,2,3* 1 Rutgers University Department of Psychology; [email protected] 2 Rutgers University Center for Cognitive Science (RUCCS) 3 Rutgers University Computer Science, Center for Biomedicine Imaging and Modelling (CBIM) * Correspondence: [email protected]; Tel.: (011) +858-445-8909 (E.B.T) Supplementary Material Sample Psychological criteria that sidelines sensory motor issues in autism: The ADOS-2 manual [1, 2], under the “Guidelines for Selecting a Module” section states (emphasis added): “Note that the ADOS-2 was developed for and standardized using populations of children and adults without significant sensory and motor impairments. Standardized use of any ADOS-2 module presumes that the individual can walk independently and is free of visual or hearing impairments that could potentially interfere with use of the materials or participation in specific tasks.” Sample Psychiatric criteria from the DSM-5 [3] that does not include sensory-motor issues: A. Persistent deficits in social communication and social interaction across multiple contexts, as manifested by the following, currently or by history (examples are illustrative, not exhaustive, see text): 1. Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social interactions. 2. Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication.
  • Mir-338-3P Functions As a Tumor Suppressor in Gastric Cancer by Targeting PTP1B

    Mir-338-3P Functions As a Tumor Suppressor in Gastric Cancer by Targeting PTP1B

    Sun et al. Cell Death and Disease DOI 10.1038/s41419-018-0611-0 Cell Death & Disease ARTICLE Open Access miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B Feng Sun1, Mengchao Yu2,JingYu2, Zhijian Liu1,XinyanZhou2,YanqingLiu2, Xiaolong Ge3,HaidongGao2, Mei Li4, Xiaohong Jiang2,SongLiu1,XiChen2 and Wenxian Guan 1 Abstract Gastric cancer (GC) is one of the most common malignant tumors and peritoneal metastasis is the primary cause for advanced GC’s mortality. Protein-tyrosine phosphatase 1B (PTP1B) functions as an oncogene and involves in carcinogenesis and cancer dissemination. However, the function and regulation of PTP1B in GC remain poorly understood. In this study, we found that PTP1B was upregulated in GC tissues and overexpression of PTP1B in vitro promoted cell migration and prevented apoptosis. Then, we predicted that PTP1B was a target of miR-338-3p and we revealed an inverse correlation between miR-338-3p levels and PTP1B protein levels in GC tissues. Next, we verified that PTP1B was inhibited by miR-338-3p via direct targeting to its 3′-untranslated regions. Moreover, overexpression of miR-338-3p in vitro attenuated GC cell migration and promoted apoptosis, and these effects could be partially reversed by reintroduction of PTP1B. Finally, we established an orthotopic xenograft model and a peritoneal dissemination model of GC to demonstrate that miR-338-3p restrained tumor growth and dissemination in vivo by targeting PTP1B. Taken together, our results highlight that PTP1B is an oncogene and is negatively regulated by miR- 1234567890():,; 1234567890():,; 338-3p in GC, which may provide new insights into novel molecular therapeutic targets for GC.
  • Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling

    Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling

    G C A T T A C G G C A T genes Review Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling Aoife A. Nolan 1, Nourhan K. Aboud 1, Walter Kolch 1,2,* and David Matallanas 1,* 1 Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland; [email protected] (A.A.N.); [email protected] (N.K.A.) 2 Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland * Correspondence: [email protected] (W.K.); [email protected] (D.M.) Abstract: Oncogenic RAS (Rat sarcoma) mutations drive more than half of human cancers, and RAS inhibition is the holy grail of oncology. Thirty years of relentless efforts and harsh disappointments have taught us about the intricacies of oncogenic RAS signalling that allow us to now get a pharma- cological grip on this elusive protein. The inhibition of effector pathways, such as the RAF-MEK-ERK pathway, has largely proven disappointing. Thus far, most of these efforts were aimed at blocking the activation of ERK. Here, we discuss RAF-dependent pathways that are regulated through RAF functions independent of catalytic activity and their potential role as targets to block oncogenic RAS signalling. We focus on the now well documented roles of RAF kinase-independent functions in apoptosis, cell cycle progression and cell migration. Keywords: RAF kinase-independent; RAS; MST2; ASK; PLK; RHO-α; apoptosis; cell cycle; cancer therapy Citation: Nolan, A.A.; Aboud, N.K.; Kolch, W.; Matallanas, D. Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling.
  • ACVR1 Antibody Cat

    ACVR1 Antibody Cat

    ACVR1 Antibody Cat. No.: 4791 Western blot analysis of ACVR1 in A549 cell lysate with ACVR1 antibody at 1 μg/mL in (A) the absence and (B) the presence of blocking peptide. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human, Mouse HOMOLOGY: Predicted species reactivity based on immunogen sequence: Bovine: (100%), Rat: (93%) ACVR1 antibody was raised against a 14 amino acid synthetic peptide near the amino terminus of the human ACVR1. IMMUNOGEN: The immunogen is located within the first 50 amino acids of ACVR1. TESTED APPLICATIONS: ELISA, WB ACVR1 antibody can be used for detection of ACVR1 by Western blot at 1 μg/mL. APPLICATIONS: Antibody validated: Western Blot in human samples. All other applications and species not yet tested. At least four isoforms of ACVR1 are known to exist. This antibody is predicted to have no SPECIFICITY: cross-reactivity to ACVR1B or ACVR1C. POSITIVE CONTROL: 1) Cat. No. 1203 - A549 Cell Lysate Properties October 1, 2021 1 https://www.prosci-inc.com/acvr1-antibody-4791.html PURIFICATION: ACVR1 Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal ISOTYPE: IgG CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ACVR1 Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/mL ACVR1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one STORAGE CONDITIONS: year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: ACVR1 ACVR1 Antibody: FOP, ALK2, SKR1, TSRI, ACTRI, ACVR1A, ACVRLK2, Activin receptor type-1, ALTERNATE NAMES: Activin receptor type I, ACTR-I ACCESSION NO.: NP_001096 PROTEIN GI NO.: 4501895 GENE ID: 90 USER NOTE: Optimal dilutions for each application to be determined by the researcher.
  • Evolution, Expression and Meiotic Behavior of Genes Involved in Chromosome Segregation of Monotremes

    Evolution, Expression and Meiotic Behavior of Genes Involved in Chromosome Segregation of Monotremes

    G C A T T A C G G C A T genes Article Evolution, Expression and Meiotic Behavior of Genes Involved in Chromosome Segregation of Monotremes Filip Pajpach , Linda Shearwin-Whyatt and Frank Grützner * School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia; fi[email protected] (F.P.); [email protected] (L.S.-W.) * Correspondence: [email protected] Abstract: Chromosome segregation at mitosis and meiosis is a highly dynamic and tightly regulated process that involves a large number of components. Due to the fundamental nature of chromosome segregation, many genes involved in this process are evolutionarily highly conserved, but duplica- tions and functional diversification has occurred in various lineages. In order to better understand the evolution of genes involved in chromosome segregation in mammals, we analyzed some of the key components in the basal mammalian lineage of egg-laying mammals. The chromosome passenger complex is a multiprotein complex central to chromosome segregation during both mitosis and meio- sis. It consists of survivin, borealin, inner centromere protein, and Aurora kinase B or C. We confirm the absence of Aurora kinase C in marsupials and show its absence in both platypus and echidna, which supports the current model of the evolution of Aurora kinases. High expression of AURKBC, an ancestor of AURKB and AURKC present in monotremes, suggests that this gene is performing all necessary meiotic functions in monotremes. Other genes of the chromosome passenger complex complex are present and conserved in monotremes, suggesting that their function has been preserved Citation: Pajpach, F.; in mammals.
  • CDK4/6 Inhibitors in Melanoma: a Comprehensive Review

    CDK4/6 Inhibitors in Melanoma: a Comprehensive Review

    cells Review CDK4/6 Inhibitors in Melanoma: A Comprehensive Review Mattia Garutti 1,*, Giada Targato 2 , Silvia Buriolla 2 , Lorenza Palmero 1,2 , Alessandro Marco Minisini 2 and Fabio Puglisi 1,2 1 CRO Aviano National Cancer Institute IRCCS, 33081 Aviano, Italy; [email protected] (L.P.); [email protected] (F.P.) 2 Department of Medicine (DAME), University of Udine, 33100 Udine, Italy; [email protected] (G.T.); [email protected] (S.B.); [email protected] (A.M.M.) * Correspondence: [email protected] Abstract: Historically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. Nonetheless, not all patients derive a benefit or a durable benefit from these therapies. To overtake this challenges, new clinically active compounds are being tested in the context of clinical trials. CDK4/6 inhibitors are drugs already available in clinical practice and preliminary evidence showed a promising activity also in melanoma. Herein we review the available literature to depict a comprehensive landscape about CDK4/6 inhibitors in melanoma. We present the molecular and genetic background that might justify the usage of these drugs, the preclinical evidence, the clinical available data, and the most promising ongoing clinical trials. Keywords: CDK4/6; CDK4; CDK6; melanoma; Palbociclib; Ribociclib; Abemaciclib Citation: Garutti, M.; Targato, G.; Buriolla, S.; Palmero, L.; Minisini, A.M.; Puglisi, F. CDK4/6 Inhibitors in Melanoma: A Comprehensive 1. Introduction Review. Cells 2021, 10, 1334.
  • Product Data Sheet

    Product Data Sheet

    Product Data Sheet ExProfileTM Human AMPK Signaling Related Gene qPCR Array For focused group profiling of human AMPK signaling genes expression Cat. No. QG004-A (4 x 96-well plate, Format A) Cat. No. QG004-B (4 x 96-well plate, Format B) Cat. No. QG004-C (4 x 96-well plate, Format C) Cat. No. QG004-D (4 x 96-well plate, Format D) Cat. No. QG004-E (4 x 96-well plate, Format E) Plates available individually or as a set of 6. Each set contains 336 unique gene primer pairs deposited in one 96-well plate. Introduction The ExProfile human AMPK signaling related gene qPCR array profiles the expression of 336 human genes related to AMPK-mediated signal transduction. These genes are carefully chosen for their close pathway correlation based on a thorough literature search of peer-reviewed publications, mainly including genes that encode AMP-activated protein kinase complex，its regulators and targets involved in many important biological processes, such as glucose uptake, β-oxidation of fatty acids and modulation of insulin secretion. This array allows researchers to study the pathway-related genes to gain understanding of their roles in the different biological processes. QG004 plate 01: 84 unique gene PCR primer pairs QG004 plate 02: 84 unique gene PCR primer pairs QG004 plate 03: 84 unique gene PCR primer pairs QG004 plate 04: 84 unique gene PCR primer pairs Shipping and storage condition Shipped at room temperate Stable for at least 6 months when stored at -20°C Array format GeneCopoeia provides five qPCR array formats (A, B, C, D, and E) suitable for use with the following real- time cyclers.
  • Supplementary Information Material and Methods

    Supplementary Information Material and Methods

    MCT-11-0474 BKM120: a potent and specific pan-PI3K inhibitor Supplementary Information Material and methods Chemicals The EGFR inhibitor NVP-AEE788 (Novartis), the Jak inhibitor I (Merck Calbiochem, #420099) and anisomycin (Alomone labs, # A-520) were prepared as 50 mM stock solutions in 100% DMSO. Doxorubicin (Adriablastin, Pfizer), EGF (Sigma Ref: E9644), PDGF (Sigma, Ref: P4306) and IL-4 (Sigma, Ref: I-4269) stock solutions were prepared as recommended by the manufacturer. For in vivo administration: Temodal (20 mg Temozolomide capsules, Essex Chemie AG, Luzern) was dissolved in 4 mL KZI/glucose (20/80, vol/vol); Taxotere was bought as 40 mg/mL solution (Sanofi Aventis, France), and prepared in KZI/glucose. Antibodies The primary antibodies used were as follows: anti-S473P-Akt (#9271), anti-T308P-Akt (#9276,), anti-S9P-GSK3β (#9336), anti-T389P-p70S6K (#9205), anti-YP/TP-Erk1/2 (#9101), anti-YP/TP-p38 (#9215), anti-YP/TP-JNK1/2 (#9101), anti-Y751P-PDGFR (#3161), anti- p21Cip1/Waf1 (#2946), anti-p27Kip1 (#2552) and anti-Ser15-p53 (#9284) antibodies were from Cell Signaling Technologies; anti-Akt (#05-591), anti-T32P-FKHRL1 (#06-952) and anti- PDGFR (#06-495) antibodies were from Upstate; anti-IGF-1R (#SC-713) and anti-EGFR (#SC-03) antibodies were from Santa Cruz; anti-GSK3α/β (#44610), anti-Y641P-Stat6 (#611566), anti-S1981P-ATM (#200-301), anti-T2609 DNA-PKcs (#GTX24194) and anti- 1 MCT-11-0474 BKM120: a potent and specific pan-PI3K inhibitor Y1316P-IGF-1R were from Bio-Source International, Becton-Dickinson, Rockland, GenTex and internal production, respectively. The 4G10 antibody was from Millipore (#05-321MG).
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
  • Human Kinome Profiling Identifies a Requirement for AMP-Activated

    Human Kinome Profiling Identifies a Requirement for AMP-Activated

    Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection Laura J. Terrya, Livia Vastagb,1, Joshua D. Rabinowitzb, and Thomas Shenka,2 aDepartment of Molecular Biology and bDepartment of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544 Contributed by Thomas Shenk, January 11, 2012 (sent for review December 29, 2011) Human cytomegalovirus (HCMV) modulates numerous cellular (7). Thus, the connections between AMPK activity and metabolic signaling pathways. Alterations in signaling are evident from the changes during HCMV infection have remained unclear. broad changes in cellular phosphorylation that occur during HCMV We confirmed the requirement for AMPK during infection, infection and from the altered activity of multiple kinases. Here we and we show that an AMPK antagonist, compound C, blocks report a comprehensive RNAi screen, which predicts that 106 cellular HCMV-induced changes to glycolysis and inhibits viral gene kinases influence growth of the virus, most of which were not expression. These studies argue that AMPK or a related, com- previously linked to HCMV replication. Multiple elements of the pound C-sensitive kinase is an essential contributor to metabolic AMP-activated protein kinase (AMPK) pathway scored in the screen. changes initiated by HCMV and provide unique insight into As a regulator of carbon and nucleotide metabolism, AMPK is poised potential antiviral strategies. to activate many of the metabolic pathways induced by HCMV infection. An AMPK inhibitor, compound C, blocked a substantial Results portion of HCMV-induced metabolic changes, inhibited the accumu- HumanKinomeScreenIdentifies Putative Effectors of HCMV Replication. lation of all HCMV proteins tested, and markedly reduced the We conducted an siRNA screen of the human kinome to perform an production of infectious progeny.
  • Saracatinib Is an Efficacious Clinical Candidate for Fibrodysplasia Ossificans Progressiva

    Saracatinib Is an Efficacious Clinical Candidate for Fibrodysplasia Ossificans Progressiva

    RESEARCH ARTICLE Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva Eleanor Williams,1 Jana Bagarova,2 Georgina Kerr,1 Dong-Dong Xia,2 Elsie S. Place,3 Devaveena Dey,2 Yue Shen,2 Geoffrey A. Bocobo,2 Agustin H. Mohedas,2 Xiuli Huang,4 Philip E. Sanderson,4 Arthur Lee,4 Wei Zheng,4 Aris N. Economides,5 James C. Smith,3 Paul B. Yu,2 and Alex N. Bullock1 1Centre for Medicines Discovery, University of Oxford, Oxford, United Kingdom. 2Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom. 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA. 5Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare congenital syndrome in which heterotopic bone is formed in soft tissues owing to dysregulated activity of the bone morphogenetic protein (BMP) receptor kinase ALK2 (also known as ACVR1). From a screen of known biologically active compounds, we identified saracatinib as a potent ALK2 kinase inhibitor. In enzymatic and cell-based assays, saracatinib preferentially inhibited ALK2, compared with other receptors of the BMP/TGF-β signaling pathway, and induced dorsalization in zebrafish embryos consistent with BMP antagonism. We further tested the efficacy of saracatinib using an inducible ACVR1Q207D-transgenic mouse line, which provides a model of heterotopic ossification (HO), as well as an inducible ACVR1R206H-knockin mouse, which serves as a genetically and physiologically faithful FOP model. In both models, saracatinib was well tolerated and potently inhibited the development of HO, even when administered transiently following soft tissue injury.